secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0000950170-24-069414
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics formalizes interim CEO compensation: $50k/month in equity, no cash/benefits/severance
--------------------------------------------------------------------------------

- Samir R. Patel appointed Interim President & CEO effective May 1; agreement signed May 31.
- Compensation entirely equity-based: $50,000/month in fully vested ordinary shares valued at monthly closing price.
- No annual bonus, employee benefits, or severance entitlements; at-will independent contractor role.
- Company may terminate agreement immediately for any reason.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024069414/0000950170-24-069414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024069414/aktx-20240531.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-069414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer